Teruki Honma

Teruki Honma

Auto-generated profile, based on publicly available information

Teruki Honma

RIKEN Center for Integrative Medical Sciences

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DIDaniel Inaoka
Daniel Inaoka
TSTomoo Shiba
Tomoo Shiba
DSDan Sato
Dan Sato
EBEmmanuel Balogun
Emmanuel Balogun
TSTsuyoshi Sasaki
Tsuyoshi Sasaki
SHShigeharu Harada
Shigeharu Harada
Recent studies on the respiratory chain of Ascaris suum showed that the mitochondrial NADH-fumarate reductase system composed of complex I, rhodoquinone and complex II plays an important role in the anaerobic energy metabolism of adult A. suum. The system is the major pathway of energy metabolism for adaptation to a hypoxic environment not only in parasitic organisms, but also in some types of human cancer cells. Thus, enzymes of the pathway are potential targets for chemotherapy. We found that flutolanil is an excellent inhibitor for A. suum complex II (IC50 = 0.058 μM) but less effectively inhibits homologous porcine complex II (IC50 = 45.9 μM). In order to account for the specificity of flutolanil to A. suum complex II from the standpoint of structural biology, we determined the crystal structures of A. suum and porcine complex IIs binding flutolanil and its derivative compounds. The structures clearly demonstrated key interactions responsible for its high specificity to A. suum complex II and enabled us to find analogue compounds, which surpass flutolanil in both potency and specificity to A. suum complex II. Structures of complex IIs binding these compounds will be helpful to accelerate structure-based drug design targeted for complex IIs.

29 January 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
DTDaisuke Takaya
Daisuke Takaya
CWChiduru Watanabe
Chiduru Watanabe
SNShunpei Nagase
Shunpei Nagase
KKKikuko Kamisaka
Kikuko Kamisaka
YOYoshio Okiyama
Yoshio Okiyama
THTeruki Honma
Teruki Honma
We developed the world’s first web-based public database for the storage, management, and sharing of fragment molecular orbital (FMO) calculation data sets describing the complex interactions between biomacromolecules, named FMO Database (https://drugdesign.riken.jp/FMODB/). Each entry in the database contains relevant background information on how the data was compiled as well as the total energy of each molecular system and interfragment interaction energy (IFIE) and pair interaction energy decomposition analysis (PIEDA) values. Currently, the database contains more than 13 600 FMO calculation data sets, and a comprehensive search function implemented at the front-end. The procedure for selecting target proteins, preprocessing the experimental structures, construction of the database, and details of the database front-end were described. Then, we demonstrated a use of the FMODB by comparing IFIE value distributions of hydrogen bond, ion-pair, and XH/π interactions obtained by FMO method to those by molecular mechanics approach. From the comparison, the statistical analysis of the data provided standard reference values for the three types of interactions that will be useful for determining whether each interaction in a given system is relatively strong or weak compared to the interactions contained within the data in the FMODB. In the final part, we demonstrate the use of the database to examine the contribution of halogen atoms to the binding affinity between human cathepsin L and its inhibitors. We found that the electrostatic term derived by PIEDA greatly correlated with the binding affinities of the halogen containing cathepsin L inhibitors, indicating the importance of QM calculation for quantitative analysis of halogen interactions. Thus, the FMO calculation data in FMODB will be useful for conducting statistical analyses to drug discovery, for conducting molecular recognition studies in structural biology, and for other studies involving quantum mechanics-based interactions.

21 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KOKeiji Ogura
Keiji Ogura
TSTomohiro Sato
Tomohiro Sato
HYHitomi Yuki
Hitomi Yuki
THTeruki Honma
Teruki Honma
Assessing the hERG liability in the early stages of drug discovery programs is important. The recent increase of hERG-related information in public databases enabled various successful applications of machine learning techniques to predict hERG inhibition. However, most of these researches constructed the datasets from only one database, limiting the predictability and scope of the models. In this study, a hERG classification model was constructed using the largest dataset for hERG inhibition built by integrating multiple databases. The integrated dataset consisted of more than 291,000 structurally diverse compounds derived from ChEMBL, GOSTAR, PubChem, and hERGCentral. The prediction model was built by support vector machine (SVM) with descriptor selection based on Non-dominated Sorting Genetic Algorithm-II (NSGA-II) to optimize the descriptor set for maximum prediction performance with the minimal number of descriptors. The SVM classification model using 72 selected descriptors and ECFP_4 structural fingerprints recorded kappa statistics of 0.733 and accuracy of 0.984 for the test set, substantially outperforming the prediction performance of the current commercial applications for hERG prediction. Finally, the applicability domain of the prediction model was assessed based on the molecular similarity between the training set and test set compounds.

6 July 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSTomohiro Sato
Tomohiro Sato
HYHitomi Yuki
Hitomi Yuki
KOKeiji Ogura
Keiji Ogura
THTeruki Honma
Teruki Honma
The inhibition of the hERG potassium channel is closely related to the prolonged QT interval, and thus assessing this risk could greatly facilitate the development of therapeutic compounds and the withdrawal of hazardous marketed drugs. The recent increase in SAR information about hERG inhibitors in public databases has led to many successful applications of machine learning techniques to predict hERG inhibition. However, most of these reports constructed their prediction models based on only one SAR database because the differences in the data format and ontology hindered the integration of the databases. In this study, we curated the hERG-related data in ChEMBL, PubChem, GOSTAR, and hERGCentral, and integrated them into the largest database about hERG inhibition by small molecules. Assessment of structural diversity using Murcko frameworks revealed that the integrated database contains more than twice as many chemical scaffolds for hERG inhibitors than any of the individual databases, and covers 18.2% of the Murcko framework-based chemical space occupied by the compounds in ChEMBL. The database provides the most comprehensive information about hERG inhibitors and will be useful to design safer compounds for drug discovery. The database is freely available at http://drugdesign.riken.jp/hERGdb/.

1 December 2017 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
CWChiduru Watanabe
Chiduru Watanabe
HWHirofumi Watanabe
Hirofumi Watanabe
KFKaori Fukuzawa
Kaori Fukuzawa
LPLorien J. Parker
Lorien J. Parker
YOYoshio Okiyama
Yoshio Okiyama
THTeruki Honma
Teruki Honma

18 March 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FSFumiyuki Shirai
Fumiyuki Shirai
TTTakeshi Tsumura
Takeshi Tsumura
YYYoko Yashiroda
Yoko Yashiroda
HYHitomi Yuki
Hitomi Yuki
HNHideaki Niwa
Hideaki Niwa
HKHiroo Koyama
Hiroo Koyama